UNSPSC 51386610: Hydrocortisone/pramoxine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class DE200. This VA Drug Class (DE200) classifies this compound as belonging to the group ANTI-INFLAMMATORY, TOPICAL.

UNSPSC 51386610 Hydrocortisone/pramoxine is a Commodity code that nominally covers pharmaceutical topical treatments, though recent state and local solicitation activity shows minimal alignment with this taxonomy designation. The one recent opportunity in the dataset is Seminole County, Florida's IFB60459723LAS, posted June 30, 2026, which seeks Naloxone and Safe Drug Deactivation Systems—products outside the hydrocortisone/pramoxine scope entirely. This mismatch suggests either a tagging error in the county's procurement system or that the code is being used as a catch-all for pharmaceutical and medical supplies beyond its nominal commodity definition. State and local health departments, county public-health agencies, and community-health programs appear to be the primary issuing bodies where related pharmaceutical procurement occurs, though the limited recent activity under this specific code makes broad characterization difficult.

Seminole County, Florida represents the sole recent opportunity on record. The county's IFB, due July 26, 2023, seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract offers an initial two-year term with a one-year renewal option, and vendors must provide unit pricing, maintain workers' compensation and commercial general liability coverage, and comply with E-Verify requirements. The procurement does not include explicit set-asides for disadvantaged enterprises. Given the single opportunity and the substantial divergence between the code's nominal scope and the actual work being solicited, this code shows little current activity relevant to hydrocortisone/pramoxine products specifically; vendors pursuing pharmaceutical procurement with state and local agencies should verify code alignment before investing bid-preparation resources.